In June, LINNC PARIS 2023 will be held in Paris, France. As a neurointerventional medical device company, NeuroSafe participated in the exhibition and brought excellent innovative products and rich solutions.
From June 5th to 7th, the Interventional Neuroradiology and Neurosurgery Symposium was held in Paris (LINNC PARIS 2023). NeuroSafe's core products such as LavaTM liquid embolic system, GluttonTM aspiration catheter, DredgerTM revascularization device, RenovaTM detachable coil system and TranaviTM microcatheter were unveiled. The three products of the LavaTM liquid embolic system, GluttonTM aspiration catheter, DredgerTM revascularization device have obtained the EU CE certification in 2021. Among them, NeuroSafe's LAVA liquid embolic system has a unique low-viscosity formula, the most complete model, better dispersion and permeability, and excellent visibility. With its innovative product design and excellent clinical research data, its clinical use has won unanimous praise from overseas doctors. The LavaTM liquid embolic system is expected to complete clinical trials in 2023 and obtain NMPA registration in 2024.
NeuroSafe's participation in LINNC PARIS 2023 this time showed that the company's products have been recognized by more and more customers in overseas markets. In the future, NeuroSafe will continue to focus on the clinical needs of doctors and patients, and provide more comprehensive and creative products and solutions for patients and doctors at home and abroad.
